Inflammaging‑driven B‑cell exosomes mediate cortical network rigidity via TNF‑α‑dependent microglial priming

Hypothesis

Aged B‑cells release TNF‑α‑rich exosomes that cross the blood‑brain barrier and prime microglia, leading to excessive synaptic pruning and cortical network rigidity. This mechanism links immunosenescence to the over‑consolidation phenotype observed in aging brains. It's becoming clear that the immune system talks to the brain via soluble factors, and exosomes are a key vehicle for this cross‑talk.

Mechanistic Rationale

Inflammaging elevates systemic TNF‑α, which not only impairs B‑cell class‑switch recombination and somatic hypermutation [2] but also loads exosomes secreted by senescent B‑cells with inflammatory cargo. These exosomes are enriched in tetraspanins (CD9, CD63, CD81) and carry membrane‑bound TNF‑α as well as downstream signaling molecules such as RIPK1 and TRAF2. Once in the circulation they can exploit age‑related increases in vascular permeability and transient opening of the blood‑brain barrier to gain access to the parenchyma. Within the brain, exosomal TNF‑α engages TNFR1 on microglia, triggering NF‑κB activation and a shift toward a primed phenotype characterized by up‑regulation of CD68, MHC‑II, and complement component C1q. Primed microglia then increase synaptic tagging via C3 deposition, accelerating complement‑mediated phagocytosis of excitatory synapses. This process reduces dendritic spine density, lowers network modularity, and promotes hypersynchrony, as shown in resting‑state fMRI studies of aged mice [4]. Importantly, the effect is not simply a loss of neurons; rather, the surviving circuits become overly stable because synaptic turnover is suppressed, limiting the ability to encode new predictions—a core feature of the over‑consolidation hypothesis. We don't see this as inevitable wear‑and‑tear but as a reversible signal imbalance that can be modulated by altering exosomal flux or microglial responsiveness.

Testable Predictions

1. Neutralizing TNF‑α with a peripheral antibody in aged mice will decrease exosomal TNF‑α levels measured in serum and CSF, reduce microglial priming (lower CD68/MHC‑II), and restore cortical network flexibility, reflected by increased modularity and decreased hypersynchrony in functional connectivity maps.
2. Isolating exosomes from young B‑cells and injecting them into aged mice will counteract the rigidity phenotype, whereas exosomes from old B‑cells will exacerbate it when transferred into young recipients, demonstrating that the cargo, not the donor age per se, drives the effect.
3. Genetic deletion of the TNF‑α receptor (TNFR1) specifically in microglia will protect aged mice from B‑cell‑induced network rigidity without altering peripheral B‑cell numbers, confirming that microglial TNFR1 is the critical downstream node.
4. Pharmacological inhibition of exosome release (e.g., with GW4869) in aged mice will lower brain TNF‑α levels and rescue cognitive flexibility in reversal‑learning tasks, providing an orthogonal approach that targets the vesicle pathway.

Experimental Design

• Animal groups: young (3 mo), old (24 mo) wild‑type mice; old mice receiving anti‑TNF‑α antibody (intraperitoneal, twice weekly); old mice receiving young‑B‑cell exosomes (intracerebroventricular, 10 µg protein); old mice receiving old‑B‑cell exosomes; young mice receiving old‑B‑cell exosomes; microglia‑specific TNFR1 knockout mice; old mice treated with GW4869 to block exosome synthesis; appropriate IgG and vehicle controls.
• Readouts: serum and CSF exosomal TNF‑α quantified by ELISA using exosome‑capture beads; flow cytometry of isolated microglia for activation markers (CD68, MHC‑II, CD86) and complement receptors; immunoblot of brain lysates for phosphorylated NF‑κB p65 and C3; two‑photon imaging of dendritic spine density in layer II/III pyramidal neurons of the primary somatosensory cortex; resting‑state fMRI acquired under light anesthesia to compute network modularity (using Louvain community detection) and global synchrony (standard deviation of BOLD signal across regions); behavioral assays for cognitive flexibility including reversal learning in a water maze and attentional set‑shifting.
• Expected outcome: If the hypothesis is correct, anti‑TNF‑α treatment, young‑B‑cell exosome transfer, microglial TNFR1 knockout, and GW4869 will each normalize microglial activation markers, increase spine density, improve network modularity, reduce hypersynchrony, and enhance performance on flexibility tasks. Conversely, old‑B‑cell exosome transfer into young mice will reproduce the aged phenotype, decreasing spine density, lowering modularity, increasing hypersynchrony, and impairing reversal learning. We can't assume that peripheral cytokine levels alone predict central outcomes; the brain‑specific readouts are essential to distinguish a true neuroimmune mechanism from systemic sickness behavior.

This framework provides a clear, falsifiable route to test whether B‑cell‑derived inflammatory exosomes drive the brain’s over‑consolidation in aging, offering a mechanistic bridge between immunosenescence and cognitive rigidity.